Pharmaceutical powerhouse GSK has announced a significant increase in profits, buoyed by robust sales in its HIV and asthma treatment sectors. However, the company has cautioned investors about a potential slowdown in growth for the upcoming year. This marks the first financial report under the leadership of new CEO Luke Miels, who succeeded Emma Walmsley at the beginning of the year.
Solid Financial Performance
GSK’s financial results reveal a turnover of £32.7 billion for 2025, representing a 4% increase from the previous year. The final quarter saw an even more pronounced growth of 6%. The company’s specialty medicines played a pivotal role in this success, with sales soaring by 17% to reach £13.5 billion. Notably, respiratory, immunology, and inflammation treatments experienced an impressive 18% increase, while sales of HIV medications climbed by 11%.
In terms of profitability, GSK reported a 7% rise in core operating profits over the past year, with the latest quarter exceeding expectations at a remarkable 14% growth. However, the outlook for 2026 suggests a moderation in this momentum, with core operating profit growth anticipated to range between 7% and 9%.
Strategic Vision Under New Leadership
In his first address to investors, Miels expressed confidence in GSK’s future, stating, “GSK delivered another strong performance in 2025, driven mainly by specialty medicines, with double-digit sales growth in respiratory, immunology and inflammation (RI&I), oncology, and HIV.” He emphasised the significance of ongoing research and development (R&D), highlighting five major product approvals and strategic acquisitions aimed at bolstering GSK’s oncology and RI&I pipeline.
Miels also underscored the importance of 2026 as a critical year for execution and operational delivery, with a strong focus on commercial launches and accelerating R&D efforts. His positive outlook aims to reassure stakeholders about the company’s sustainable growth trajectory in the long term.
Analyst Insights
Sheena Berry, a healthcare analyst at Quilter Cheviot, characterised GSK’s year-end performance as commendable. She remarked, “This was the first full-year update under new CEO Luke Miels, and it represents a steady and credible start.” While acknowledging a slight moderation in growth projections, Berry highlighted the company’s strengths in vaccines and HIV, suggesting that GSK is well-positioned for sustained growth.
Market Reactions and Future Challenges
As GSK prepares for the upcoming year, market observers will be keenly watching how the company navigates the anticipated slowdown in sales growth. Factors such as increased competition in the pharmaceutical sector, potential regulatory changes, and the ongoing need for innovation in drug development could all play significant roles in shaping GSK’s performance.
Why it Matters
GSK’s latest financial results not only reflect its current market position but also set the stage for what lies ahead in the competitive pharmaceutical landscape. With new leadership steering the company through a period of strategic change, stakeholders must remain vigilant. The balance between maintaining growth momentum and managing market challenges will be critical as GSK seeks to leverage its strengths in specialty medicines while preparing for future uncertainties.
